Claritev Announces Q3 EPS of $4.23 Compared to ($24.25) in the Previous Year
Q3 Financial Performance: Claritev reported Q3 revenue of $245.96 million, an increase from $230.50 million the previous year, and ended the quarter with $39.2 million in unrestricted cash and cash equivalents.
Strategic Focus: The company declared 2025 as the "Year of the Turn," indicating a shift in strategy towards growth and execution of their Strategic Plan, referred to as "The Way Up."
Commitment to Healthcare: CEO Travis Dalton emphasized the company's mission to make healthcare affordable and transparent, highlighting the importance of building relationships within the healthcare ecosystem.
Future Outlook: Claritev's increased full-year guidance reflects confidence in their strategic direction and the foundation laid for future success.
Trade with 70% Backtested Accuracy
Analyst Views on CTEV
About CTEV
About the author


- Mental Health Resource Launch: Claritev Cares and the Elizabeth Dole Foundation have collaborated to release mental health insurance guides for military and veteran caregivers, aimed at helping them better understand and utilize healthcare benefits, thereby alleviating emotional and logistical burdens on caregivers.
- High Depression Rates: A RAND study indicates that 42% of military caregivers meet criteria for depression, nearly four times the rate of non-caregivers, with 20% having considered suicide, highlighting the urgent need for support and the significance of the new resources.
- Information Integration Platform: The new guidance consolidates reliable mental health insurance information into a trusted online platform, assisting caregivers in navigating complex healthcare systems with greater confidence, thus enhancing their access to necessary medical services.
- Commitment to Social Responsibility: The Chair of Claritev Cares emphasized that this collaboration reflects a strong commitment to military and veteran caregivers, aiming to provide practical and accessible resources to support these families who have served the nation and help them better cope with healthcare challenges.
- Antitrust Investigation Launched: The U.S. Department of Justice's antitrust division initiated a criminal price-fixing investigation into Claritev on May 14, 2026, focusing on its Data iSight pricing tool, which could expose the company to legal liabilities.
- Significant Stock Drop: Following the announcement of the investigation, Claritev's stock plummeted from $23.47 to $13.87 per share, representing a 41% decline, reflecting severe market concerns regarding the company's future prospects.
- Investor Rights Protection: Bragar Eagel & Squire is representing Claritev shareholders in investigating potential claims, urging affected investors to reach out to understand their legal rights, highlighting a commitment to investor protection.
- Law Firm Background: Bragar Eagel & Squire is a nationally recognized law firm specializing in securities, derivative, and commercial litigation, with extensive legal practice experience aimed at providing robust legal support for investors.
- Dell Upgrade: Susquehanna upgraded Dell from neutral to positive, citing increased confidence in a sustainable 8-10% operating margin and a 6% free cash flow margin, which supports a potential rerating of its EV/sales multiple to 3x, indicating strong market potential.
- Viper Energy Initiation: RBC initiated coverage of Viper Energy with an Outperform rating and a $58 price target, highlighting its advantages in scale and core Permian focus, positioning it as a best-in-class mineral and royalty company.
- SentinelOne Buy Rating: Bank of America upgraded SentinelOne from neutral to buy, viewing its solid quarterly performance as a strong entry point after an 18% decline in after-hours trading, reflecting confidence in its future growth prospects.
- XPeng Upgrade: Macquarie upgraded XPeng from neutral to outperform, noting its volume growth in the Chinese EV market, while future investments in humanoids and robotaxis provide additional upside potential for its stock.
- Antitrust Investigation Launched: On May 14, 2026, the U.S. Department of Justice's antitrust division initiated a criminal price-fixing investigation into Claritev Corporation, focusing on its Data iSight pricing tool, which may violate federal securities laws, potentially impacting the company's reputation and operations.
- Significant Stock Price Drop: Following the investigation news, Claritev's stock plummeted from $23.47 to $13.87 per share, a 41% decline, directly reflecting market uncertainty regarding the company's future and a loss of investor confidence.
- Law Firm Involvement: Kirby McInerney LLP is investigating on behalf of Claritev investors to assess the potential for legal claims, indicating heightened scrutiny of the company's senior management's possible misconduct and the implications for shareholder interests.
- Investor Rights Protection: Although no lawsuit has been filed yet, Kirby McInerney LLP encourages all investors who purchased or acquired Claritev securities to reach out to discuss their rights, emphasizing the necessity and urgency of legal support in light of the ongoing investigation.
- Antitrust Investigation Launched: On May 14, 2026, the U.S. Department of Justice's antitrust division initiated a criminal price-fixing investigation into Claritev Corporation, focusing on its Data iSight pricing tool, which may violate federal securities laws, impacting the company's reputation and market trust.
- Significant Stock Price Drop: Following the investigation news, Claritev's stock plummeted from $23.47 per share on May 14 to $13.87 on May 15, representing a 41% decline, which directly affects investor confidence and may lead to subsequent lawsuits.
- Law Firm Involvement: Kirby McInerney LLP has reminded Claritev investors of the ongoing investigation to determine if claims can be filed, indicating the company faces legal risks that could affect its future operations.
- Investor Rights Protection: The firm encourages investors who purchased or acquired Claritev securities to contact them to discuss their rights, highlighting the importance of investor protection and potentially impacting the company's future investment appeal.
- Antitrust Investigation Launched: The U.S. Department of Justice's antitrust division initiated a criminal price-fixing investigation into Claritev on May 14, 2026, focusing on its Data iSight pricing tool, which may expose the company to legal liabilities.
- Significant Stock Drop: Following the investigation news, Claritev's stock plummeted from $23.47 per share on May 14 to $13.87 on May 15, marking a 41% decline, indicating market concerns about the company's future.
- Investor Rights Protection: Bragar Eagel & Squire is representing Claritev shareholders in investigating potential claims, urging affected investors to contact the firm to discuss their legal rights, highlighting the importance of investor advocacy.
- Law Firm Background: Bragar Eagel & Squire is a nationally recognized law firm specializing in securities, derivative, and commercial litigation, demonstrating its extensive experience in handling similar cases.









